ClinicalTrials.gg
CompletedNCT01265667Updated Nov 18, 2020Results posted

Trial of CF101 to Treat Patients With Psoriasis

A Phase 2/3 interventional study of CF101 and Placebo in Plaque Psoriasis, sponsored by Can-Fite BioPharma. Completed at 18 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-18.

Sponsored by Can-Fite BioPharma · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
293
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies in Psoriasis with a site in Bulgaria — 1 open to participants now, 4 under way, 4 of them phase 3. Psoriasis · Bulgaria.

Enrollment
37th of 46
293 · median 509
Started
2011
with 1 other
Phase 2/3
2 of 46
none open now
Registered
9th of 46
by date
Lead sponsor
2 of 46
Can-Fite BioPharma

Among the 46 studies in Psoriasis with a site in Bulgaria, this one is the 37th largest by enrollment, is one of 2 that started in 2011, is one of 2 in phase 2/3, and was the 9th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 46 studies in Psoriasis with a site in Bulgaria is open now. Recruiting first, the newest first:

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Psoriasis with a site in Bulgaria, or all of them as a file.
02

Study summary

Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.

Read the detailed description

Eligible patients will be randomly assigned to parallel dosing groups of CF101 2 mg or matching placebo tablets twice daily (BID) in a 1:1 ratio for the 16-week controlled treatment period. Approximately 94 patients will be assigned to each group.

Medication will be taken orally BID for 16 weeks in a double-blinded fashion. At the end of 16 weeks, all patients assigned to CF101 will continue CF101, while patients originally assigned to placebo will be reassigned to CF101.

Assessment of peripheral blood mononuclear cell (PBMC) adenosine A3 receptor (A3AR) expression at baseline and during treatment with CF101 in selected sites.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • Plaque psoriasis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 80 years of age, inclusive
  • Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area involvement ≥10%
  • Duration of psoriasis of at least 6 months
  • Physician global assessment (PGA) ≥3
  • Candidate for systemic treatment or phototherapy for psoriasis
  • (ECG) is normal
  • Females of must have a negative serum pregnancy test
  • Females of child-bearing potential must be willing to use 2 methods of
  • Ability to complete the study in compliance with the protocol
  • Ability to understand and provide written .

Exclusion criteria

Exclusion Criteria:

  • Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis
  • Treatment with systemic retinoids, , or agents within 4 weeks of the Baseline visit
  • Treatment with high potency topical corticosteroids, keratolytics, or coal tar within 2 weeks of the Baseline visit
  • Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit
  • Treatment with a biological agent within a period of time equal to 5 times its circulating half-life
  • Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit
  • Serum creatinine level greater than 1.5 times the laboratory's
  • Liver aminotransferase levels greater than the laboratory's upper limit of normal
  • Significant acute or chronic medical or psychiatric illness
  • Participation in another drug or vaccine trial concurrently or within 30 days prior to Screening visit.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
293 participants (actual)

Study arms

  • Experimental
    CF101 2 mg

    CF101 2mg oral tablets

    Drug: CF101

  • Placebo comparator
    Placebo

    Placebo oral tablets

    Drug: Placebo

Interventions

  • DrugCF101

    orally q12h

    Also known as: IB-MECA

  • DrugPlacebo

    orally q12h

    Also known as: Dummy pills

06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks

    Achievement of PASI 75 indicates a 75% reduction in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Subjects Achieving PGA of 0 or 1

    PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe)

    Time frame: 16 weeks

  2. Numberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 75

    Achievement of PASI 50 or 75 indicates a 50% and 75% reduction respectively in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)

    Time frame: 16 weeks

  3. Nature and Frequency of Adverse Events

    Assessment of safety of CF101 in this patient population by gathering adverse event data based on history, vital signs, physical examination, and laboratory data

    Time frame: 32 weeks

07

Results

Posted Sep 20, 2017

Participant flow

Participant flow — Overall Study
MilestoneCF101 2 mgPlacebo
Started145148
Completed125135
Not completed2013

Outcome measures

PrimaryNumber of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks

Achievement of PASI 75 indicates a 75% reduction in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks
ParticipantsCF101 2 mgPlacebo
Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks1210
SecondaryNumber of Subjects Achieving PGA of 0 or 1

PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe)

Time frame:
16 weeks
Reported as:
Number · participants
Number of Subjects Achieving PGA of 0 or 1
participantsCF101 2 mgPlacebo
Number of Subjects Achieving PGA of 0 or 195
SecondaryNumberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 75

Achievement of PASI 50 or 75 indicates a 50% and 75% reduction respectively in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)

Time frame:
16 weeks
Reported as:
Number · participants
Numberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 75
participantsCF101 2 mgPlacebo
Numberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 753117
SecondaryNature and Frequency of Adverse Events

Assessment of safety of CF101 in this patient population by gathering adverse event data based on history, vital signs, physical examination, and laboratory data

Time frame:
32 weeks
Reported as:
Count of participants · Participants
Nature and Frequency of Adverse Events
ParticipantsCF101 2 mgPlacebo
Any3729
Gastrointestinal disorders83
Infections and infestations1013
Musculoskeletal and connective tissue disorders52
Nervous system disorders60
Renal and urinary disorders54

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CF101 2 mg—0/145 (0%)24/145 (16.6%)
Placebo—0/148 (0%)15/148 (10.1%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCF101 2 mgPlacebo
HeadacheNervous system disorders4/1450/148
Urinary tract infectionInfections and infestations2/1454/148
DiarrhoeaGastrointestinal disorders3/1451/148
ArthralgiaMusculoskeletal and connective tissue disorders2/1450/148
NasopharyngitisInfections and infestations2/1452/148
Abdominal painGastrointestinal disorders2/1451/148
Dry mouthGastrointestinal disorders2/1450/148
NauseaGastrointestinal disorders2/1450/148
HaematuriaRenal and urinary disorders2/1452/148
ProteinuriaRenal and urinary disorders2/1451/148

Baseline characteristics

Age, Continuous
Age, Continuous(years)CF101 2mgPlaceboTotal
Mean48.3 ± 13.5750.0 ± 13.9649.2 ± 13.77
Sex: Female, Male
Sex: Female, Male(Participants)CF101 2mgPlaceboTotal
Female5453107
Male9195186
08

Study locations

18 sites
  • Mount Sinai School of Medicine
    New York, New York, United States
  • UMHAT "G.stranski"
    Pleven, 5800,, Bulgaria
  • MHAT "Tokuda hospital Sofia"
    Sofia,, 1407, Bulgaria
  • DCC "Fokus-5"-MIOC, EOOD
    Sofia,, 1463, Bulgaria
  • Military Medical Acdemy (MMA)
    Sofia, 1606, Bulgaria
  • MHAT "Doverie"
    Sofia, 1632,, Bulgaria
  • City Center for Skin and Venereal Disease
    Sofia, Bulgaria
  • Multiprofile Hospital for Active Ttreatment
    Stara Zagora, 6003, Bulgaria
  • MHAT Varna at MMA Sofia
    Varna,, 9010,, Bulgaria
  • Haemek Medical Center
    Afula, Israel
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Rabin Medical Center
    Petah Tiqva, 49100, Israel
  • Centrul Medical Euromed
    Bucuresti, Romania
  • Spitalul Clinic Dermato-Venerice
    Bucuresti, Romania
  • Emergency County Clinical Hospital
    Cluj-Napoca, Romania
  • Spitalul Clinic Judetean de Urgenta Constanta
    Constanta,, 900622, Romania
  • Spit Clinic Judetean de Urgenta Sf Spiridon Iasi
    Iasi, 700368,, Romania
  • County Clinical Emergency Hospital
    Sibiu, Romania
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Mar 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2017, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2010
First posted
Dec 23, 2010
Start
Jul 2011
Primary completionActual
Mar 2015
CompletionActual
May 2015
Results first posted
Sep 20, 2017
Last update
Nov 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01265667
Lead sponsor
Can-Fite BioPharma
Responsible party
Sponsor
First posted
Dec 23, 2010
Start date
Jul 2011
Primary completion
Mar 2015
Completion
May 2015
Results posted
Sep 20, 2017
Last update
Nov 18, 2020

Study contacts

Michael H Silverman, MD
study director · Can-Fite BioPharma

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CF101

Start the discussion